Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer.
about
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerCytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell.Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cellsLung cancer. 9: Molecular biology of lung cancer: clinical implications.Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).Platinum drugs in the treatment of non-small-cell lung cancerTargeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanismsPrognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer.Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Advances in personalized therapy for lung cancer.Synergistic Effect of Notch-3-Specific Inhibition and Paclitaxel in Non-Small Cell Lung Cancer (NSCLC) Cells Via Activation of The Intrinsic Apoptosis Pathway.Basal and zinc-induced metallothionein in resistance to cadmium, cisplatin, zinc, and tertbutyl hydroperoxide: studies using MT knockout and antisense-downregulated MT in mammalian cells.A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.[The molecular markers related to personalized therapy of non-small cell lung cancer].
P2860
Q28396304-6D59C0DC-EF99-47A4-9B18-32F685D0FD62Q33704464-3F432085-CB76-4D3A-9B8E-9982B57B788FQ33750796-A70612E3-2531-4FA2-AB85-0886E4A02448Q33889144-9928D672-C852-4065-A220-D754ED8CDE1AQ33972805-B2230A6E-C202-4EBC-9288-7C4652E80551Q34367452-0AB38C80-A2A7-44AE-973D-5C937E46322EQ34954760-D066961C-39D1-4E91-8855-05FEF2346C5DQ36751705-33ECD45F-F4E5-40A4-BB88-BDE4C979D06AQ37996270-6CC0E330-C135-4A6E-9005-3F8F3394809AQ38030053-E67CC68A-2A23-469E-B51A-A406D1BF7AF3Q38127786-4C4BE157-67DE-48B9-AF33-5F62E3FC7CCEQ41360028-D1336D16-DC1B-42C0-9CA2-2B30CE963915Q42483739-9F5BB5BA-D260-4C38-8657-62DA9F2AF319Q43174266-6BFBEE13-E846-4D73-A055-6750BDC1A32EQ55329630-1551DC1C-46AD-477B-BFB9-449A158DAA88Q55437999-D5DF659E-4BBF-4FDB-968E-AA97F409F2C8
P2860
Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Predicting response to paclita ...... in non-small cell lung cancer.
@ast
Predicting response to paclita ...... in non-small cell lung cancer.
@en
Predicting response to paclita ...... in non-small cell lung cancer.
@nl
type
label
Predicting response to paclita ...... in non-small cell lung cancer.
@ast
Predicting response to paclita ...... in non-small cell lung cancer.
@en
Predicting response to paclita ...... in non-small cell lung cancer.
@nl
prefLabel
Predicting response to paclita ...... in non-small cell lung cancer.
@ast
Predicting response to paclita ...... in non-small cell lung cancer.
@en
Predicting response to paclita ...... in non-small cell lung cancer.
@nl
P1433
P1476
Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer
@en
P2093
P356
10.1016/S0093-7754(01)90058-2
P433
4 Suppl 14
P577
2001-08-01T00:00:00Z